COVID-19: not the time for health economists? A plea for more proactive health economic involvement.
作者信息
Schulenburg J-Matthias Graf von der
机构信息
Leibniz University Hannover, Hannover, Germany.
出版信息
Eur J Health Econ. 2021 Sep;22(7):1001-1004. doi: 10.1007/s10198-021-01349-2. Epub 2021 Jul 13.
Abstract
摘要
相似文献
1
COVID-19: not the time for health economists? A plea for more proactive health economic involvement.新冠疫情：健康经济学家缺席？呼吁其更积极地参与其中
Eur J Health Econ. 2021 Sep;22(7):1001-1004. doi: 10.1007/s10198-021-01349-2. Epub 2021 Jul 13.
2
Quantifying the Impact of Public Perceptions on Vaccine Acceptance Using Behavioral Economics.利用行为经济学量化公众认知对疫苗接种接受度的影响。
Front Public Health. 2020 Dec 3;8:608852. doi: 10.3389/fpubh.2020.608852. eCollection 2020.
3
Vaccinating children against SARS-CoV-2.为儿童接种新冠病毒疫苗。
BMJ. 2021 May 13;373:n1197. doi: 10.1136/bmj.n1197.
4
Covid-19, equity, and inclusiveness.新冠疫情、公平与包容性。
BMJ. 2021 Jun 29;373:n1631. doi: 10.1136/bmj.n1631.
5
Chinese consumers' willingness to get a COVID-19 vaccine and willingness to pay for it.中国消费者对 COVID-19 疫苗的接种意愿和支付意愿。
PLoS One. 2021 May 4;16(5):e0250112. doi: 10.1371/journal.pone.0250112. eCollection 2021.
6
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
7
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.新型冠状病毒候选载体疫苗 MVA-SARS-2-S 的免疫原性和疗效的临床前疫苗接种研究。
Proc Natl Acad Sci U S A. 2021 Jul 13;118(28). doi: 10.1073/pnas.2026207118.
8
Economic and Behavioral Influencers of Vaccination and Antimicrobial Use.疫苗接种和抗菌药物使用的经济和行为影响因素。
Front Public Health. 2020 Dec 21;8:614113. doi: 10.3389/fpubh.2020.614113. eCollection 2020.
9
[Vaccination immunology in SARS-CoV-2].[新型冠状病毒肺炎中的疫苗接种免疫学]
Ugeskr Laeger. 2021 Mar 15;183(11).
10
Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination.韩国健康医护人员接种辉瑞-生物科技疫苗第二剂后 1 至 2 周内的 SARS-CoV-2 抗体阳性率。
J Korean Med Sci. 2021 May 31;36(21):e158. doi: 10.3346/jkms.2021.36.e158.
引用本文的文献
1
The impact of COVID-19 pandemic on the world's major economies: based on a multi-country and multi-sector CGE model.新冠疫情对世界主要经济体的影响：基于多国多部门 CGE 模型的分析。
Front Public Health. 2024 Mar 19;12:1338677. doi: 10.3389/fpubh.2024.1338677. eCollection 2024.
2
The implications of globalization on COVID-19 vaccination in Europe.全球化对欧洲 COVID-19 疫苗接种的影响。
Sci Rep. 2022 Oct 19;12(1):17474. doi: 10.1038/s41598-022-21493-w.
本文引用的文献
1
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.英国新冠病毒疫苗接种与保持社交距离相结合的潜在健康和经济价值：基于传播模型的未来情景分析与经济评估
Lancet Infect Dis. 2021 Jul;21(7):962-974. doi: 10.1016/S1473-3099(21)00079-7. Epub 2021 Mar 18.
2
The economics of global COVID vaccine administration during a pandemic - Why continue skin alcohol preparation as a costly but ineffective practice?大流行期间全球新冠疫苗接种的经济学——为何继续将皮肤酒精消毒作为一种成本高昂却无效的做法？
Vaccine. 2021 Feb 22;39(8):1175-1177. doi: 10.1016/j.vaccine.2020.12.082. Epub 2021 Jan 21.
3
Measuring the cost of a pediatric vaccine administration in the UK.测量英国儿科疫苗接种的成本。
Vaccine. 2018 Jan 4;36(2):237-242. doi: 10.1016/j.vaccine.2017.11.042. Epub 2017 Dec 6.
4
The cost of immunising at the general practice level.基层医疗层面的免疫接种成本。
J Prim Health Care. 2009 Dec;1(4):286-96.
Zotero 插件